Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1911 1
1928 1
1929 1
1931 1
1932 1
1933 1
1934 1
1935 1
1936 1
1937 2
1938 2
1951 1
1964 1
1967 1
1968 3
1970 3
1971 3
1972 2
1973 3
1974 2
1976 1
1977 3
1978 3
1979 3
1980 3
1981 6
1982 4
1983 4
1984 5
1985 8
1986 8
1987 2
1988 4
1989 5
1990 7
1991 2
1992 3
1993 4
1994 3
1995 7
1996 6
1997 1
1998 2
1999 5
2000 4
2001 6
2002 6
2003 2
2004 1
2005 2
2006 5
2007 2
2008 5
2009 7
2010 10
2011 9
2012 17
2013 10
2014 23
2015 18
2016 17
2017 20
2018 19
2019 8
2020 16
2021 19
2022 27
2023 38
2024 32

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

430 results

Results by year

Filters applied: . Clear all
Page 1
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.
Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, Felip E, Broderick SR, Brahmer JR, Swanson SJ, Kerr K, Wang C, Ciuleanu TE, Saylors GB, Tanaka F, Ito H, Chen KN, Liberman M, Vokes EE, Taube JM, Dorange C, Cai J, Fiore J, Jarkowski A, Balli D, Sausen M, Pandya D, Calvet CY, Girard N; CheckMate 816 Investigators. Forde PM, et al. N Engl J Med. 2022 May 26;386(21):1973-1985. doi: 10.1056/NEJMoa2202170. Epub 2022 Apr 11. N Engl J Med. 2022. PMID: 35403841 Free PMC article. Clinical Trial.
Hereditary Ovarian Cancer: Towards a Cost-Effective Prevention Strategy.
Ghose A, Bolina A, Mahajan I, Raza SA, Clarke M, Pal A, Sanchez E, Rallis KS, Boussios S. Ghose A, et al. Int J Environ Res Public Health. 2022 Sep 23;19(19):12057. doi: 10.3390/ijerph191912057. Int J Environ Res Public Health. 2022. PMID: 36231355 Free PMC article. Review.
Antibody Drug Conjugates in Urological Cancers: A Review of the Current Landscape.
Ghose A, Lapitan P, Apte V, Ghosh A, Kandala A, Basu S, Parkes J, Shinde SD, Boussios S, Sharma A, Das P, Vasdev N, Rebuzzi SE, Ürün Y, Kanesvaran R, Maniam A, Banna GL. Ghose A, et al. Curr Oncol Rep. 2024 Jun;26(6):633-646. doi: 10.1007/s11912-024-01524-7. Epub 2024 Apr 23. Curr Oncol Rep. 2024. PMID: 38652426 Review.
Stage 3 N2 Lung Cancer: A Multidisciplinary Therapeutic Conundrum.
Carter L, Apte V, Shukla A, Ghose A, Mamidi R, Petohazi A, Makker S, Banerjee S, Boussios S, Banna GL. Carter L, et al. Among authors: ghose a. Curr Oncol Rep. 2024 Jan;26(1):65-79. doi: 10.1007/s11912-023-01486-2. Epub 2024 Jan 2. Curr Oncol Rep. 2024. PMID: 38180692 Free PMC article. Review.
Renal Cell Cancer - Insights in Drug Resistance Mechanisms.
Aweys H, Lewis D, Sheriff M, Rabbani RD, Lapitan P, Sanchez E, Papadopoulos V, Ghose A, Boussios S. Aweys H, et al. Among authors: ghose a. Anticancer Res. 2023 Nov;43(11):4781-4792. doi: 10.21873/anticanres.16675. Anticancer Res. 2023. PMID: 37909991 Review.
Diagnostic biomarkers in ovarian cancer: advances beyond CA125 and HE4.
Ghose A, McCann L, Makker S, Mukherjee U, Gullapalli SVN, Erekkath J, Shih S, Mahajan I, Sanchez E, Uccello M, Moschetta M, Adeleke S, Boussios S. Ghose A, et al. Ther Adv Med Oncol. 2024 Feb 29;16:17588359241233225. doi: 10.1177/17588359241233225. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 38435431 Free PMC article. Review.
430 results